Navigation Links
Transcept Pharmaceuticals Receives Notice of Allowance for Second U.S. Patent Application Covering Intermezzo(R)
Date:12/14/2009

he USPTO; the potential favorable outcome of additional patent prosecution and issuance efforts in favor of Intermezzo®; expectations with respect to the activities of Transcept and Purdue and the satisfaction of conditions and obligations under the parties' United States License and Collaboration Agreement (the Collaboration Agreement); expectations regarding potential milestone payments under the Collaboration Agreement; the ability of Transcept to satisfy the issues raised by the FDA in the Complete Response Letter; and the timing of regulatory submissions and decisions with respect to the NDA for Intermezzo® with the FDA. Such statements are based on management's current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to, whether Transcept is able to satisfy concerns expressed by FDA in its October 28, 2009 Complete Response Letter and otherwise satisfy FDA that the Intermezzo® NDA is sufficient to approve Intermezzo® for its intended indication and any further delays in, and the final form of, any FDA approval of Intermezzo®; possible claims of patent invalidity; obtaining patent issuance, maintaining adequate patent protection and successfully enforcing such patent claims against third parties; commercializing Intermezzo® without violating the intellectual property rights of others; a decision by Purdue to terminate the Collaboration Agreement, even if the Intermezzo® NDA is approved; obtaining and maintaining Hatch-Waxman exclusivity for Intermezzo® and other difficulties or delays in, clinical development, market acceptance and commercialization of Intermezzo®.


    Contact:

    Transcept Pharmaceuticals, Inc.
    Greg Mann
    Director, Corporate Communications
    (510) 215-3567
    '/>"/>
SOURCE Transcept Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Transcept Pharmaceuticals Announces Intent to Submit New Drug Application for Intermezzo(R) in Third Quarter 2008
2. Transcept Pharmaceuticals Submits New Drug Application for Intermezzo(R) for Treatment of Middle-of-the-Night Awakenings
3. Transcept Pharmaceuticals to Report First Quarter 2009 Results
4. Transcept Pharmaceuticals Receives Complete Response Letter from FDA on Intermezzo(R) New Drug Application
5. Transcept Pharmaceuticals to Report Third Quarter 2009 Results and Host Conference Call on November 12
6. Transcept Pharmaceuticals to Present at Lazard Capital Markets Healthcare Conference on November 17
7. Transcept Pharmaceuticals Reports Third Quarter 2009 Financial Results
8. Transcept Pharmaceuticals Scheduled to Meet With FDA to Discuss Intermezzo(R) Complete Response Letter
9. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
10. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
11. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... (NASDAQ: LMNX ) today announced financial results for ... operating highlights for the quarter include the following: ... percent to $58.9 million, over the second quarter of ... by 22 percent to $24.2 million over results from ... 2015 royalty revenue by 17 percent to $11.1 million ...
(Date:8/3/2015)... Inc. (NYSE: DPLO ), the nation,s largest independent specialty ... 2015. All comparisons, unless otherwise noted, are to the quarter ... Highlights include: , Revenue of $808 million, an ... dispensed of 234,000, an increase of 19% , Gross ... $22.7 million, an increase of 287% or $16.8 million ...
(Date:8/3/2015)... N.Y. , Aug. 3, 2015 ... Wilmot Cancer Institute to the OmniSeq SM ... Roswell Park Cancer Institute (RPCI) and announced it ... that support a physician-driven, collaborative approach to genomic ... outcomes.  Wilmot Cancer Institute is a rapidly expanding, ...
Breaking Medicine Technology:Luminex Corporation Reports Record 2nd Quarter 2015 Results 2Luminex Corporation Reports Record 2nd Quarter 2015 Results 3Luminex Corporation Reports Record 2nd Quarter 2015 Results 4Luminex Corporation Reports Record 2nd Quarter 2015 Results 5Luminex Corporation Reports Record 2nd Quarter 2015 Results 6Luminex Corporation Reports Record 2nd Quarter 2015 Results 7Luminex Corporation Reports Record 2nd Quarter 2015 Results 8Luminex Corporation Reports Record 2nd Quarter 2015 Results 9Luminex Corporation Reports Record 2nd Quarter 2015 Results 10Luminex Corporation Reports Record 2nd Quarter 2015 Results 11Luminex Corporation Reports Record 2nd Quarter 2015 Results 12Luminex Corporation Reports Record 2nd Quarter 2015 Results 13Luminex Corporation Reports Record 2nd Quarter 2015 Results 14Luminex Corporation Reports Record 2nd Quarter 2015 Results 15Luminex Corporation Reports Record 2nd Quarter 2015 Results 16Diplomat Announces 2nd Quarter 2015 Financial Results 2Diplomat Announces 2nd Quarter 2015 Financial Results 3Diplomat Announces 2nd Quarter 2015 Financial Results 4Diplomat Announces 2nd Quarter 2015 Financial Results 5Diplomat Announces 2nd Quarter 2015 Financial Results 6Diplomat Announces 2nd Quarter 2015 Financial Results 7Diplomat Announces 2nd Quarter 2015 Financial Results 8Diplomat Announces 2nd Quarter 2015 Financial Results 9Diplomat Announces 2nd Quarter 2015 Financial Results 10Diplomat Announces 2nd Quarter 2015 Financial Results 11Diplomat Announces 2nd Quarter 2015 Financial Results 12Diplomat Announces 2nd Quarter 2015 Financial Results 13Diplomat Announces 2nd Quarter 2015 Financial Results 14Diplomat Announces 2nd Quarter 2015 Financial Results 15Diplomat Announces 2nd Quarter 2015 Financial Results 16Diplomat Announces 2nd Quarter 2015 Financial Results 17Diplomat Announces 2nd Quarter 2015 Financial Results 18OmniSeq Adds Wilmot Cancer Institute to its Collaboration-Based Treatment Network 2OmniSeq Adds Wilmot Cancer Institute to its Collaboration-Based Treatment Network 3
... 2011 Just days after the one year anniversary ... representatives at Novartis Pharmaceuticals Corporation, the law firm of ... class action on behalf of female sales representatives at ... amended complaint, there is an entirely new class of ...
... Reportlinker.com announces that a new market research ... Chinese Pharmaceutical Regulatory Report 2011 ... This report includes a brief ... in China, as well as a discussion ...
Cached Medicine Technology:Bayer's Discrimination Lawsuit Now Requires Extra-Strength Cure 2Bayer's Discrimination Lawsuit Now Requires Extra-Strength Cure 3Bayer's Discrimination Lawsuit Now Requires Extra-Strength Cure 4Reportlinker Adds Chinese Pharmaceutical Regulatory Report 2011 2
(Date:8/4/2015)... ... August 04, 2015 , ... Mesothelioma researchers in ... back: Retreatment may be a viable option. Surviving Mesothelioma has just posted an ... According to surgeons at the University of New South Wales, peritoneal mesothelioma ...
(Date:8/4/2015)... ... August 04, 2015 , ... Montclair State University and Atlantic ... first of its kind in New Jersey, which starting this Fall will help prepare ... Graduate School partnered with Atlantic Health System, one of the largest health care organizations ...
(Date:8/4/2015)... ... August 04, 2015 , ... T.E.N., an information technology and security executive ... ISE® Lions’ Den and Jungle Lounge 2015, which will be held from 3-6:30 p.m. ... the event, eight emerging security vendors, known as “Gazelles,” will go head-to-head with the ...
(Date:8/4/2015)... , ... August 04, 2015 , ... ... homes and other long-term care facilities, today announced details of the Advanced level ... homes and centers. , Providigm’s QAPI Accreditation program , introduced in 2013, ...
(Date:8/4/2015)... ... , ... It’s been called “cosmetics heaven,” “mecca for make-up,” and “where Hollywood ... in LA. Now MENAJI is part of that experience acting as a "bridge" grooming ... been a favorite of makeup artists and hair pros as well as celebrities for ...
Breaking Medicine News(10 mins):Health News:New Research Reveals Some Patients Experience Extended Mesothelioma Survival with Repeat Treatment, According to Surviving Mesothelioma 2Health News:Atlantic Health System & Montclair State University Launch Graduate Program in Arts & Health 2Health News:Atlantic Health System & Montclair State University Launch Graduate Program in Arts & Health 3Health News:T.E.N. Releases Pitch Schedule for The ISE® Lions Den & Jungle Lounge 2015 2Health News:T.E.N. Releases Pitch Schedule for The ISE® Lions Den & Jungle Lounge 2015 3Health News:T.E.N. Releases Pitch Schedule for The ISE® Lions Den & Jungle Lounge 2015 4Health News:Nursing Homes Achieving New Advanced Accreditation See Improved Measures of Quality, Better Occupancy Rates 2Health News:Nursing Homes Achieving New Advanced Accreditation See Improved Measures of Quality, Better Occupancy Rates 3Health News:MENAJI Shines in Make-Up Mecca for Stars 2
... Digirad Corporation (Nasdaq: DRAD ), today reported it ... generating consistent profitability and positive cash flow. Net income ... CEO Todd Clyde said, "We are pleased to report significant ... previously communicated our 2009 goals as: , ...
... Andersen to discuss weight management system and book, "Dr. A,s Habits ... , ... Westerville-Dublin, Ohio (PRWEB) April 30, 2009 -- Dr. ... Shape For Life and author of "Dr A,s Habits of Health" ...
... April 30, 2009 - Management Health Solutions, Inc. (MHS) , ... health care industry has announced improvements to their Clinical Inventory Valuation ... the clinical inventory supply process and unlock huge savings. www.mhsinc.com ... ...
... a correlation between higher levels of glutamate, which occurs naturally in ... in multiple sclerosis patients. , ... (Vocus) April 30, ... of glutamate, which occurs naturally in the brain as a byproduct ...
... destroy airborne biological contaminants including swine influenza (H1N1 virus). , ... ... Technologies has been receiving inquiries following the recent swine influenza ... as in other parts of the world. Sanuvox UV Air Sterilization ...
... survey shows women focus on others, at expense of ... More than two-thirds of American women interviewed for a ... say that the nation,s sagging economy has negatively affected ... The findings also indicate women may be neglecting their ...
Cached Medicine News:Health News:Digirad Corporation Reports First Quarter 2009 Financial Results 2Health News:Digirad Corporation Reports First Quarter 2009 Financial Results 3Health News:Digirad Corporation Reports First Quarter 2009 Financial Results 4Health News:Digirad Corporation Reports First Quarter 2009 Financial Results 5Health News:Digirad Corporation Reports First Quarter 2009 Financial Results 6Health News:Physician and Author to Share Clinically Proven System for Permanent Weight Loss and Optimal Health in Westerville and Dublin, Ohio Areas 2Health News:Management Health Solutions, Inc. Announces Release v1.0 to Clinical Inventory Valuation Solution 2Health News:Glutamate Identified As Predictor of Disease Progression in Multiple Sclerosis 2Health News:Glutamate Identified As Predictor of Disease Progression in Multiple Sclerosis 3Health News:Sanuvox UV Air Sterilization Systems Ability to Destroy Airborne Type A Influenza including Swine Flu (H1N1) 2Health News:Sanuvox UV Air Sterilization Systems Ability to Destroy Airborne Type A Influenza including Swine Flu (H1N1) 3Health News:Women's Mental Health Hit Hard by Recession, Yet Many Show Resilience and Resourcefulness in Coping With Stress 2Health News:Women's Mental Health Hit Hard by Recession, Yet Many Show Resilience and Resourcefulness in Coping With Stress 3Health News:Women's Mental Health Hit Hard by Recession, Yet Many Show Resilience and Resourcefulness in Coping With Stress 4
Irrigating Cystotome, Straight, 25 g. Overall length 15 mm. 5/box....
Irrigating Capsulorhexis Cystotome. Formed blunt tip, 25 g. Overall length 22 mm. 5/box....
Irrigating Cystotome, formed, 23 g., 12 mm curved tip. Overall length 14 mm. 5/box....
Retrobulbar Needle, 25 g. Atkinson style bevel. Overall length 38 mm. 5/box....
Medicine Products: